**Core Concept**
Levosimendan is a calcium sensitizer used in the management of heart failure. It works by increasing the sensitivity of cardiac myocytes to calcium without increasing the intracellular calcium concentration.

**Why the Correct Answer is Right**
Levosimendan acts by binding to the calcium receptor on the cardiac sarcoplasmic reticulum, which increases the sensitivity of the myofilaments to calcium. This results in improved contractility without increasing the oxygen demand of the heart. Additionally, levosimendan has vasodilatory properties due to its ability to open adenylate cyclase-sensitive potassium channels.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is not provided, but we can discuss the possible mechanisms of action of levosimendan. If it's one of the options, it could be incorrect if it's related to an increase in intracellular calcium, which is not the primary mechanism of action of levosimendan.
* **Option B:** If this option is related to the opening of ATP-sensitive potassium channels, it would be incorrect as levosimendan primarily acts by opening adenylate cyclase-sensitive potassium channels.
* **Option C:** If this option is related to the inhibition of phosphodiesterase, it would be incorrect as levosimendan does not primarily act through this mechanism.
* **Option D:** If this option is related to the direct inhibition of the sodium-potassium pump, it would be incorrect as levosimendan does not primarily act through this mechanism.

**Clinical Pearl / High-Yield Fact**
Levosimendan is a useful agent in the management of decompensated heart failure, particularly in patients who are inotropic-refractory. It has a unique mechanism of action that increases cardiac contractility without increasing the oxygen demand of the heart.

**Correct Answer:** C